Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Advanced Hepatocellular Carcinoma
ChiCTR-OPC-17011019Phase 4Recruiting
- Sponsor
- Affiliated Huai'an Hospital of Xuzhou Medical University
- Start
- Mar 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Affiliated Huai'an Hospital of Xuzhou Medical University. Primary endpoint: Progression-Free Survival. Started Mar 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-OPC-17011019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17011019.